EUVIMEDEUVIMED entdecken
Crossref

Proteomic profiling reveals selaginellin A-induced blockade of cell cycle in MDA-MB-231 cells

Jing Wen, Shuai-Cong Ni, Xiao-Lin-Mo Ma-Hai, Yuan Liu, Xin-Jia Yan

Bioscience, Biotechnology, and Biochemistry · 2025

DOI: 10.1093/bbb/zbaf139 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioscience, Biotechnology, and Biochemistry, 2025. Verfasst von Jing Wen und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Sichuan College of Traditional Chinese Medicine, Mianyang, China. Hauptthemen laut MEDLINE: Proteomics, Cell Cycle, Breast Neoplasms. Die Arbeit nennt 22 Literaturangaben. Gefördert von: Natural Science Foundation of Sichuan, Funding Project of Sichuan College of Traditional Chinese Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Selaginellin A (Sela A), a derivative from Selaginella tamariscina, exerts antitriple-negative breast cancer effects in MDA-MB-231 cells. Proteomic profiling identified 1136 differentially expressed proteins after Sela A treatment, predominantly downregulated (n = 889). Enrichment analyses revealed that Sela A significantly downregulated pathways critical for DNA repair, replication, and cell cycle progression, while upregulating ribosomal biogenesis and protein processing. Mechanistically, Sela A acts as a PTP1B inhibitor (IC50 = 7.4 μm), binding key residues (PHE-182, GLU-186). This inhibition activates the mechanistic target of rapamycin complex 1 (mTOR). Consequently, mTOR activation stimulates ribosomal synthesis but concurrently triggers a p70S6K-mediated negative feedback loop, degrading IRS1. IRS1 loss suppresses Akt signaling, reducing expression of cell cycle proteins and inducing G1-phase arrest. Thus, Sela A may block MDA-MB-231 cell proliferation via PTP1B inhibition driving mTOR/IRS1/Akt dysregulation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProteomicsCell CycleBreast NeoplasmsHumansCell Line, TumorTOR Serine-Threonine KinasesProtein Tyrosine Phosphatase, Non-Receptor Type 1Cell ProliferationInsulin Receptor Substrate ProteinsProto-Oncogene Proteins c-aktSignal TransductionFemaleMechanistic Target of Rapamycin Complex 1MDA-MB-231 Cells

Stichwörter der Autor:innen

MDA-MB-231 cellsPTP1BSelaginellin ATNBCcell cycle arrest

Substanzen

TOR Serine-Threonine KinasesProtein Tyrosine Phosphatase, Non-Receptor Type 1Insulin Receptor Substrate ProteinsProto-Oncogene Proteins c-aktIRS1 protein, humanPTPN1 protein, humanMTOR protein, humanMechanistic Target of Rapamycin Complex 1

Autor:innen und Institutionen

  • School of Pharmacy, Sichuan College of Traditional Chinese Medicine, Mianyang, China.
  • College of Pharmacy and Food, Southwest Minzu University, Chengdu, China.
  • Sichuan Provincial Qiang-Yi Medicinal Resources Protection and Utilization Technology Engineering Laboratory, Chengdu, China.
  • Qinghai-Tibetan Plateau Ethnic Medicinal Resources Protection and Utilization Key Laboratory of National Ethnic Affairs Commission of the People's Republic of China, Chengdu.

Förderung

  • Natural Science Foundation of Sichuan
  • Funding Project of Sichuan College of Traditional Chinese Medicine

Zitieren

APA

Wen, J., Ni, S. C., Ma-Hai, X. L., Liu, Y., & Yan, X. J. (2025). Proteomic profiling reveals selaginellin A-induced blockade of cell cycle in MDA-MB-231 cells. Bioscience, Biotechnology, and Biochemistry. https://doi.org/10.1093/bbb/zbaf139

Vancouver

Wen J, Ni SC, Ma-Hai XL, Liu Y, Yan XJ. Proteomic profiling reveals selaginellin A-induced blockade of cell cycle in MDA-MB-231 cells. Bioscience, Biotechnology, and Biochemistry. 2025. doi:10.1093/bbb/zbaf139

BibTeX
@article{Wen2025,
  author = {Wen, Jing and Ni, Shuai-Cong and Ma-Hai, Xiao-Lin-Mo and Liu, Yuan and Yan, Xin-Jia},
  title = {Proteomic profiling reveals selaginellin A-induced blockade of cell cycle in MDA-MB-231 cells},
  journal = {Bioscience, Biotechnology, and Biochemistry},
  year = {2025},
  doi = {10.1093/bbb/zbaf139}
}
Kostenlos starten →